Pyxis Oncology (PYXS) Operating Leases (2020 - 2025)

Pyxis Oncology (PYXS) has 5 years of Operating Leases data on file, last reported at $17.0 million in Q4 2025.

• Operating Leases for Q4 2025 came in at $17.0 million, down 9.07% year-over-year; the trailing twelve-month figure through Dec 2025 was $17.0 million (down 9.07% YoY), and the FY2025 annual result was $17.0 million, down 9.07% from the prior year.
• Operating Leases eased to $17.0 million in Q4 2025 per PYXS's latest filing, from $17.4 million in the prior quarter.
• Over five years, Operating Leases peaked at $20.7 million in Q2 2023 and troughed at $15.7 million in Q2 2022.
• A 4-year average of $18.5 million and a median of $18.9 million in 2022 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2025: Operating Leases soared 32.2% in 2023, then retreated 9.07% in 2025.
• A 4-year view of Operating Leases shows it stood at $18.9 million in 2022, then increased by 6.23% to $20.1 million in 2023, then slipped by 7.21% to $18.6 million in 2024, then dropped by 9.07% to $17.0 million in 2025.
• Business Quant data shows PYXS's Operating Leases at $17.0 million in Q4 2025, $17.4 million in Q3 2025, and $17.8 million in Q2 2025.